J

Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
SSE:688076

Watchlist Manager
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
SSE:688076
Watchlist
Price: 57.2 CNY -4.06% Market Closed
Market Cap: 12.6B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+25%
Revenue
Forecast
+47%
Operating Income
Forecast
+67%
Net Income
Forecast
+69%

Wall Street
Price Targets

Price Targets Summary
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

Wall Street analysts forecast Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd is 71.6 CNY with a low forecast of 70.9 CNY and a high forecast of 73.71 CNY.

Lowest Forecast
Wall Street Target
70.9 CNY
24% Upside
Average Forecast
Wall Street Target
71.6 CNY
25% Upside
Highest Forecast
Wall Street Target
73.71 CNY
29% Upside
Lowest
Price Target
70.9 CNY
24% Upside
Average
Price Target
71.6 CNY
25% Upside
Highest
Price Target
73.71 CNY
29% Upside
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd Competitors:
Price Targets
600422
KPC Pharmaceuticals Inc
40% Upside
PBH
Prestige Consumer Healthcare Inc
10% Upside
NOVN
Novartis AG
14% Upside
SUNPHARMA
Sun Pharmaceutical Industries Ltd
21% Upside
600422
KPC Pharmaceuticals Inc
40% Upside
PBH
Prestige Consumer Healthcare Inc
10% Upside
NOVN
Novartis AG
14% Upside
SUNPHARMA
Sun Pharmaceutical Industries Ltd
21% Upside
H
3692
Hansoh Pharmaceutical Group Company Ltd
7% Upside
AJANTPHARM
Ajanta Pharma Ltd
20% Upside
VIRP
Virbac SA
32% Upside
MRK
Merck & Co Inc
42% Upside

Revenue
Forecast

Revenue Estimate
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

The compound annual growth rate of Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's revenue for the next 3 years is 47%.

N/A
Past Growth
47%
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

The compound annual growth rate of Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's operating income for the next 3 years is 67%.

N/A
Past Growth
67%
Estimated Growth
Estimates Accuracy
-26%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

The compound annual growth rate of Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's net income for the next 3 years is 69%.

N/A
Past Growth
69%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's stock price target?
Price Target
71.6 CNY

According to Wall Street analysts, the average 1-year price target for Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd is 71.6 CNY with a low forecast of 70.9 CNY and a high forecast of 73.71 CNY.

What is Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
47%

The compound annual growth rate of Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's revenue for the next 3 years is 47%.

What is Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
67%

The compound annual growth rate of Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's operating income for the next 3 years is 67%.

What is Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
69%

The compound annual growth rate of Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's net income for the next 3 years is 69%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 243,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.